Continued Access to Darunavir/Ritonavir (DRV/Rtv) in HIV-1-Infected Adults (Roll Over Patients From C211, C214 & C229)

Trial Profile

Continued Access to Darunavir/Ritonavir (DRV/Rtv) in HIV-1-Infected Adults (Roll Over Patients From C211, C214 & C229)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Darunavir (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 20 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 20 May 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017.
    • 20 Nov 2015 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top